Table 1.
Cervix (N=250) | Vagina (N=28) | Vulva (N=46) | Total (N=324) | P-value | |
---|---|---|---|---|---|
| |||||
Diagnosis, n (%) | |||||
Pre-invasive disease1 | 229 (92%) | 28 (100%) | 41 (89%) | 298 (92%) | |
Cancer | 21 (8%) | 0 (0%) | 5 (11%) | 26 (8%) | |
Study Center, n (%) | <0.0012 | ||||
MD Anderson Cancer Center | 112 (45%) | 24 (86%) | 42 (91%) | 178 (55%) | |
LBJ Hospital | 138 (55%) | 4 (14%) | 4 (9%) | 146 (45%) | |
Age | <0.0013 | ||||
Median (IQR) | 41 (34, 52) | 56.5 (48, 61.5) | 60.5 (51, 65) | 45 (36, 57) | |
Race, n (%) | 0.8662 | ||||
Asian | 6 (2%) | 0 (0%) | 0 (0%) | 6 (2%) | |
Black or African American | 27 (11%) | 3 (11%) | 7 (15%) | 37 (11%) | |
White | 205 (82%) | 24 (86%) | 39 (85%) | 268 (83%) | |
American Indian / Alaska Native | 1 (0%) | 0 (0%) | 0 (0%) | 1 (0%) | |
Subject declined to answer | 1 (0%) | 0 (0%) | 0 (0%) | 1 (0%) | |
Unknown | 10 (4%) | 1 (4%) | 0 (0%) | 11 (3%) | |
Ethnicity, n (%) | <0.0012 | ||||
Hispanic or Latina | 142 (57%) | 4 (14%) | 4 (9%) | 150 (46%) | |
Not Hispanic or Latina | 107 (43%) | 24 (86%) | 42 (91%) | 173 (54%) | |
Missing | 1 | 0 | 0 | 1 | |
Menopausal Status, n (%) | <0.0012 | ||||
Pre-Menopausal | 171 (74%) | 6 (21%) | 12 (27%) | 189 (62%) | |
Post-Menopausal | 60 (26%) | 22 (79%) | 32 (73%) | 114 (38%) | |
Missing | 19 | 0 | 2 | 21 | |
HIV Status, n (%) | 0.3202 | ||||
Negative | 231 (99%) | 26 (96%) | 41 (98%) | 298 (98%) | |
Positive | 3 (1%) | 1 (4%) | 1 (2%) | 5 (2%) | |
Unknown | 16 | 1 | 4 | 21 | |
Previous HPV vaccine? n (%) | 0.6252 | ||||
No | 175 (71%) | 22 (81%) | 37 (80%) | 234 (73%) | |
Yes | 5 (2%) | 0 (0%) | 0 (0%) | 5 (2%) | |
Unknown | 67 (27%) | 5 (19%) | 9 (20%) | 81 (25%) | |
Missing | 3 | 1 | 0 | 4 |
Diagnoses included for pre-invasive disease: cervix = CIN 2/CIN 3/HSIL/AIS, vagina = VAIN 2/VAIN 3/HSIL, vulva = VIN 2/VIN 3
Fisher Exact p-value
Kruskal-Wallis p-value;
Two patients had cervical diagnosis CIN 2/CIN 3 and vaginal diagnosis VAIN2/VAIN3. They are included in the Cervix group.